News Room
Technophage Receives Regulatory Approval to Initiate Phase 1/2a TP-122 Clinical Study in Europe
We are pleased to share an important milestone for Technophage: the Phase 1/2a clinical study TP-122_101A has recently received the necessary…
Technophage Recognized as PME Líder 2025
Once more we are thrilled to announce that Technophage has been recognized by IAPMEI, I.P. – Agência para a Competitividade e Inovação with the PME…
TP-102 Phase 2b End of Study Marks Key Step Toward Phase 3 Development
We are pleased to share that last Friday marked an important milestone for Technophage with the End of Study of the TP-102 Phase 2b clinical trial….
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
Technophage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology